GlassScriptPhysician profile
Kimberly C Agent
NPI 1871805820
$2,800.48
in general payments reported to CMS, 2019-2025
28 companies · $557 in 2025
The $557 reported for 2025 was more than what 76% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $405 · 2022: $494 · 2023: $675 · 2024: $670 · 2025: $557.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,902.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,902.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $903.08 | 2021-2025 | Farxiga, Breztri, Airsupra |
| Novo Nordisk INC | $349.59 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $211.58 | 2021-2025 | Ofev |
| Abbvie INC. | $205.94 | 2021-2025 | Dalvance, Ubrelvy, Qulipta |
| Takeda Pharmaceuticals U.S.A., INC. | $193.07 | 2021-2023 | Trintellix |
| Abbott Laboratories | $124.45 | 2022-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Glaxosmithkline, LLC. | $123.96 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $114.40 | 2021-2023 | Xifaxan |
| Phathom Pharmaceuticals, INC. | $87.61 | 2023-2025 | Voquezna |
| Lilly USA, LLC | $61.99 | 2021-2024 | Mounjaro, Zepbound |
| Verona Pharma, INC. | $59.94 | 2025 | Ohtuvayre |
| Averitas Pharma INC. | $50.38 | 2025 | Qutenza |
| Medtronic, INC. | $41.93 | 2023-2024 | Intellis Adaptivestim |
| Ironwood Pharmaceuticals, INC | $33.64 | 2023-2024 | Linzess |
| Pfizer INC. | $28.04 | 2021-2022 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $25.66 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $20.38 | 2023 | Dificid |
| Lundbeck LLC | $19.79 | 2024 | Vyepti |
| Axsome Therapeutics, INC. | $18.82 | 2025 | Auvelity |
| Sumitomo Pharma America, INC. | $18.61 | 2024 | Gemtesa |
| Novartis Pharmaceuticals Corporation | $16.93 | 2024 | |
| Amgen INC. | $16.22 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $15.77 | 2025 | |
| Inari Medical, INC. | $14.21 | 2024 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Exact Sciences Corporation | $13.79 | 2023 | Cologuard Collection Kit |
| Astellas Pharma US INC | $13.41 | 2023 | Veozah |
| Eisai INC. | $13.11 | 2022 | |
| Genentech USA, INC. | $4.18 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kimberly Agent listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.